<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240823180909&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240823180909&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Fri, 23 Aug 2024 22:09:09 +0000</lastbuilddate>
<pubDate>Fri, 23 Aug 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Reflections From the Field: Ensuring Member Engagement</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39177567/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240823180909&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 12:S0735-1097(24)07962-2. doi: 10.1016/j.jacc.2024.07.021. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39177567/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240823180909&v=2.18.0.post9+e462414">39177567</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.021>10.1016/j.jacc.2024.07.021</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39177567</guid>
<pubDate>Fri, 23 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Cathleen Biga</dc:creator>
<dc:creator>Juan Aranda</dc:creator>
<dc:date>2024-08-23</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reflections From the Field: Ensuring Member Engagement</dc:title>
<dc:identifier>pmid:39177567</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.021</dc:identifier>
</item>
<item>
<title>Meet the First Authors</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39177505/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240823180909&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Aug 16;135(5):552-553. doi: 10.1161/RES.0000000000000687. Epub 2024 Aug 15.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39177505/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240823180909&v=2.18.0.post9+e462414">39177505</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000687>10.1161/RES.0000000000000687</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39177505</guid>
<pubDate>Fri, 23 Aug 2024 06:00:00 -0400</pubDate>
<dc:date>2024-08-23</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Meet the First Authors</dc:title>
<dc:identifier>pmid:39177505</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000687</dc:identifier>
</item>
<item>
<title>Oxysterol Sensing Through GPR183 Triggers Endothelial Senescence in Hypertension</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39176657/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240823180909&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: This study discovers a previously unrecognized role of GPR183 in promoting endothelial senescence. Pharmacological targeting of GPR183 may be an innovative therapeutic strategy for hypertension and its associated complications.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Aug 23. doi: 10.1161/CIRCRESAHA.124.324722. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Despite endothelial dysfunction being an initial step in the development of hypertension and associated cardiovascular/renal injuries, effective therapeutic strategies to prevent endothelial dysfunction are still lacking. GPR183 (G protein-coupled receptor 183), a recently identified G protein-coupled receptor for oxysterols and hydroxylated metabolites of cholesterol, has pleiotropic roles in lipid metabolism and immune responses. However, the role of GPR183 in the regulation of endothelial function remains unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Endothelial-specific GPR183 knockout mice were generated and used to examine the role of GPR183 in endothelial senescence by establishing 2 independent hypertension models: desoxycorticosterone acetate/salt-induced and Ang II (angiotensin II)-induced hypertensive mice. Echocardiography, transmission electron microscopy, blood pressure measurement, vasorelaxation response experiments, flow cytometry analysis, and chromatin immunoprecipitation analysis were performed in this study.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Endothelial GPR183 was significantly induced in hypertensive mice, which was further confirmed in renal biopsies from subjects with hypertensive nephropathy. Endothelial-specific deficiency of GPR183 markedly alleviated cardiovascular and renal injuries in hypertensive mice. Moreover, we found that GPR183 regulated endothelial senescence in both hypertensive mice and aged mice. Mechanistically, GPR183 disrupted circadian signaling by inhibiting PER1 (period 1) expression, thereby facilitating endothelial senescence and dysfunction through the cAMP/PKA (protein kinase A)/CREB (cAMP-response element binding protein) signaling pathway. Importantly, pharmacological inhibition of the oxysterol-GPR183 axis by NIBR189 or clotrimazole ameliorated endothelial senescence and cardiovascular/renal injuries in hypertensive mice.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This study discovers a previously unrecognized role of GPR183 in promoting endothelial senescence. Pharmacological targeting of GPR183 may be an innovative therapeutic strategy for hypertension and its associated complications.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39176657/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240823180909&v=2.18.0.post9+e462414">39176657</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324722>10.1161/CIRCRESAHA.124.324722</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39176657</guid>
<pubDate>Fri, 23 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Qingqing Chu</dc:creator>
<dc:creator>Yujia Li</dc:creator>
<dc:creator>Jichao Wu</dc:creator>
<dc:creator>Yanjiao Gao</dc:creator>
<dc:creator>Xiangyun Guo</dc:creator>
<dc:creator>Jing Li</dc:creator>
<dc:creator>Hang Lv</dc:creator>
<dc:creator>Min Liu</dc:creator>
<dc:creator>Wei Tang</dc:creator>
<dc:creator>Peng Zhan</dc:creator>
<dc:creator>Tao Zhang</dc:creator>
<dc:creator>Huili Hu</dc:creator>
<dc:creator>Hong Liu</dc:creator>
<dc:creator>Jinpeng Sun</dc:creator>
<dc:creator>Xiaojie Wang</dc:creator>
<dc:creator>Fan Yi</dc:creator>
<dc:date>2024-08-23</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Oxysterol Sensing Through GPR183 Triggers Endothelial Senescence in Hypertension</dc:title>
<dc:identifier>pmid:39176657</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324722</dc:identifier>
</item>
<item>
<title>DdmDE eliminates plasmid invasion by DNA-guided DNA targeting</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39173632/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240823180909&amp;v=2.18.0.post9+e462414
      <description>Horizontal gene transfer is a key driver of bacterial evolution, but it also presents severe risks to bacteria by introducing invasive mobile genetic elements. To counter these threats, bacteria have developed various defense systems, including prokaryotic Argonautes (pAgos) and the DNA defense module DdmDE system. Through biochemical analysis, structural determination, and in vivo plasmid clearance assays, we elucidate the assembly and activation mechanisms of DdmDE, which eliminates small,...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Aug 13:S0092-8674(24)00822-5. doi: 10.1016/j.cell.2024.07.028. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Horizontal gene transfer is a key driver of bacterial evolution, but it also presents severe risks to bacteria by introducing invasive mobile genetic elements. To counter these threats, bacteria have developed various defense systems, including prokaryotic Argonautes (pAgos) and the DNA defense module DdmDE system. Through biochemical analysis, structural determination, and in vivo plasmid clearance assays, we elucidate the assembly and activation mechanisms of DdmDE, which eliminates small, multicopy plasmids. We demonstrate that DdmE, a pAgo-like protein, acts as a catalytically inactive, DNA-guided, DNA-targeting defense module. In the presence of guide DNA, DdmE targets plasmids and recruits a dimeric DdmD, which contains nuclease and helicase domains. Upon binding to DNA substrates, DdmD transitions from an autoinhibited dimer to an active monomer, which then translocates along and cleaves the plasmids. Together, our findings reveal the intricate mechanisms underlying DdmDE-mediated plasmid clearance, offering fundamental insights into bacterial defense systems against plasmid invasions.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39173632/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240823180909&v=2.18.0.post9+e462414">39173632</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.07.028>10.1016/j.cell.2024.07.028</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39173632</guid>
<pubDate>Thu, 22 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Xiao-Yuan Yang</dc:creator>
<dc:creator>Zhangfei Shen</dc:creator>
<dc:creator>Chen Wang</dc:creator>
<dc:creator>Kotaro Nakanishi</dc:creator>
<dc:creator>Tian-Min Fu</dc:creator>
<dc:date>2024-08-22</dc:date>
<dc:source>Cell</dc:source>
<dc:title>DdmDE eliminates plasmid invasion by DNA-guided DNA targeting</dc:title>
<dc:identifier>pmid:39173632</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.07.028</dc:identifier>
</item>
<item>
<title>The modified RNA base acp&lt;sup>;3&lt;/sup>;U is an attachment site for N-glycans in glycoRNA</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39173631/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240823180909&amp;v=2.18.0.post9+e462414
      <description>GlycoRNA consists of RNAs modified with secretory N-glycans that are presented on the cell surface. Although previous work supported a covalent linkage between RNA and glycans, the direct chemical nature of the RNA-glycan connection was not described. Here, we develop a sensitive and scalable protocol to detect and characterize native glycoRNAs. Leveraging RNA-optimized periodate oxidation and aldehyde ligation (rPAL) and sequential window acquisition of all theoretical mass spectra (SWATH-MS),...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Aug 15:S0092-8674(24)00838-9. doi: 10.1016/j.cell.2024.07.044. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">GlycoRNA consists of RNAs modified with secretory N-glycans that are presented on the cell surface. Although previous work supported a covalent linkage between RNA and glycans, the direct chemical nature of the RNA-glycan connection was not described. Here, we develop a sensitive and scalable protocol to detect and characterize native glycoRNAs. Leveraging RNA-optimized periodate oxidation and aldehyde ligation (rPAL) and sequential window acquisition of all theoretical mass spectra (SWATH-MS), we identified the modified RNA base 3-(3-amino-3-carboxypropyl)uridine (acp<sup>3</sup>U) as a site of attachment of N-glycans in glycoRNA. rPAL offers sensitivity and robustness as an approach for characterizing direct glycan-RNA linkages occurring in cells, and its flexibility will enable further exploration of glycoRNA biology.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39173631/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240823180909&v=2.18.0.post9+e462414">39173631</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.07.044>10.1016/j.cell.2024.07.044</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39173631</guid>
<pubDate>Thu, 22 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Yixuan Xie</dc:creator>
<dc:creator>Peiyuan Chai</dc:creator>
<dc:creator>Nicholas A Till</dc:creator>
<dc:creator>Helena Hemberger</dc:creator>
<dc:creator>Charlotta G Lebedenko</dc:creator>
<dc:creator>Jennifer Porat</dc:creator>
<dc:creator>Christopher P Watkins</dc:creator>
<dc:creator>Reese M Caldwell</dc:creator>
<dc:creator>Benson M George</dc:creator>
<dc:creator>Jonathan Perr</dc:creator>
<dc:creator>Carolyn R Bertozzi</dc:creator>
<dc:creator>Benjamin A Garcia</dc:creator>
<dc:creator>Ryan A Flynn</dc:creator>
<dc:date>2024-08-22</dc:date>
<dc:source>Cell</dc:source>
<dc:title>The modified RNA base acp&lt;sup>;3&lt;/sup>;U is an attachment site for N-glycans in glycoRNA</dc:title>
<dc:identifier>pmid:39173631</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.07.044</dc:identifier>
</item>
<item>
<title>In memoriam: Akira Endo</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39172705/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240823180909&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 22:ehae470. doi: 10.1093/eurheartj/ehae470. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39172705/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240823180909&v=2.18.0.post9+e462414">39172705</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae470>10.1093/eurheartj/ehae470</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39172705</guid>
<pubDate>Thu, 22 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Alberico L Catapano</dc:creator>
<dc:creator>Angela Pirillo</dc:creator>
<dc:creator>Lale Tokgözoğlu</dc:creator>
<dc:date>2024-08-22</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>In memoriam: Akira Endo</dc:title>
<dc:identifier>pmid:39172705</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae470</dc:identifier>
</item>
<item>
<title>The Anterior Mitral Valve Leaflet Prolapse as a Key to Diagnosis of ALCAPA Syndrome</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39168574/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240823180909&amp;v=2.18.0.post9+e462414
      <description>Anomalous origin of the left coronary artery from the pulmonary artery (ALCAPA syndrome) is a rare congenital coronary abnormality carrying a poor prognosis. We present a clinical case series of ALCAPA-related anterior mitral valve leaflet prolapse and discuss its mechanism as a key to suspicion of ALCAPA syndrome.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 27;84(9):868-873. doi: 10.1016/j.jacc.2024.06.021.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Anomalous origin of the left coronary artery from the pulmonary artery (ALCAPA syndrome) is a rare congenital coronary abnormality carrying a poor prognosis. We present a clinical case series of ALCAPA-related anterior mitral valve leaflet prolapse and discuss its mechanism as a key to suspicion of ALCAPA syndrome.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39168574/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240823180909&v=2.18.0.post9+e462414">39168574</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.021>10.1016/j.jacc.2024.06.021</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39168574</guid>
<pubDate>Wed, 21 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Taida Ivanauskiene</dc:creator>
<dc:creator>Gitana Zuoziene</dc:creator>
<dc:creator>Diana Zakarkaite</dc:creator>
<dc:creator>Virgilijus Tarutis</dc:creator>
<dc:creator>Sigita Glaveckaite</dc:creator>
<dc:date>2024-08-21</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The Anterior Mitral Valve Leaflet Prolapse as a Key to Diagnosis of ALCAPA Syndrome</dc:title>
<dc:identifier>pmid:39168574</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.021</dc:identifier>
</item>
<item>
<title>Effect of Semaglutide on Epicardial Adipose Tissue in Type 2 Diabetes: Insights From the STOP (Semaglutide Treatment effect On coronary atherosclerosis Progression) Randomized Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39168573/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240823180909&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 27;84(9):865-867. doi: 10.1016/j.jacc.2024.05.065.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39168573/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240823180909&v=2.18.0.post9+e462414">39168573</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.065>10.1016/j.jacc.2024.05.065</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39168573</guid>
<pubDate>Wed, 21 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Venkat Sanjay Manubolu</dc:creator>
<dc:creator>Suvasini Lakshmanan</dc:creator>
<dc:creator>April Kinninger</dc:creator>
<dc:creator>Khadije Ahmad</dc:creator>
<dc:creator>Shriraj Susarla</dc:creator>
<dc:creator>Hoon J Seok</dc:creator>
<dc:creator>Sajad Hamal</dc:creator>
<dc:creator>Suraj Dahal</dc:creator>
<dc:creator>Sion K Roy</dc:creator>
<dc:creator>Matthew J Budoff</dc:creator>
<dc:date>2024-08-21</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Effect of Semaglutide on Epicardial Adipose Tissue in Type 2 Diabetes: Insights From the STOP (Semaglutide Treatment effect On coronary atherosclerosis Progression) Randomized Trial</dc:title>
<dc:identifier>pmid:39168573</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.065</dc:identifier>
</item>
<item>
<title>Catheter Ablation for Atrial Fibrillation in Advanced Heart Failure: Can We Trust the CASTLE-HTx Trial?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39168572/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240823180909&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 27;84(9):862-864. doi: 10.1016/j.jacc.2024.06.020.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39168572/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240823180909&v=2.18.0.post9+e462414">39168572</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.020>10.1016/j.jacc.2024.06.020</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39168572</guid>
<pubDate>Wed, 21 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Nathan Mewton</dc:creator>
<dc:creator>Florian Zores</dc:creator>
<dc:creator>Milton Packer</dc:creator>
<dc:date>2024-08-21</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Catheter Ablation for Atrial Fibrillation in Advanced Heart Failure: Can We Trust the CASTLE-HTx Trial?</dc:title>
<dc:identifier>pmid:39168572</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.020</dc:identifier>
</item>
<item>
<title>Treatment of Transcatheter Aortic Valve Thrombosis: JACC Review Topic of the Week</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39168571/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240823180909&amp;v=2.18.0.post9+e462414
      <description>Transcatheter aortic valve (TAV) thrombosis may manifest as subclinical leaflet thrombosis (SLT) and clinical valve thrombosis. SLT is relatively common (10%-20%) after transcatheter aortic valve replacement, but clinical implications are uncertain. Clinical valve thrombosis is rare (1.2%) and associated with bioprosthetic valve failure, neurologic or thromboembolic events, heart failure, and death. Treatment for TAV thrombosis has been understudied. In principle, anticoagulation may prevent TAV...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 27;84(9):848-861. doi: 10.1016/j.jacc.2024.05.064.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Transcatheter aortic valve (TAV) thrombosis may manifest as subclinical leaflet thrombosis (SLT) and clinical valve thrombosis. SLT is relatively common (10%-20%) after transcatheter aortic valve replacement, but clinical implications are uncertain. Clinical valve thrombosis is rare (1.2%) and associated with bioprosthetic valve failure, neurologic or thromboembolic events, heart failure, and death. Treatment for TAV thrombosis has been understudied. In principle, anticoagulation may prevent TAV thrombosis. Non-vitamin K oral anticoagulants, as compared to antiplatelet therapy, are associated with reduced incidence of SLT, although at the cost of higher bleeding and all-cause mortality risk. We present an overview of existing literature for management of TAV thrombosis and propose a rational treatment algorithm. Vitamin K antagonists or non-vitamin K oral anticoagulants are the cornerstone of antithrombotic treatment. In therapy-resistant or clinically unstable patients, ultraslow, low-dose infusion of thrombolytics seems effective and safe and may be preferred over redo-transcatheter aortic valve replacement or explant surgery.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39168571/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240823180909&v=2.18.0.post9+e462414">39168571</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.064>10.1016/j.jacc.2024.05.064</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39168571</guid>
<pubDate>Wed, 21 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Rik Adrichem</dc:creator>
<dc:creator>Josep Rodes Cabau</dc:creator>
<dc:creator>Roxana Mehran</dc:creator>
<dc:creator>Duk-Woo Park</dc:creator>
<dc:creator>Jurrien M Ten Berg</dc:creator>
<dc:creator>Ole de Backer</dc:creator>
<dc:creator>Christian Hengstenberg</dc:creator>
<dc:creator>Ricardo P J Budde</dc:creator>
<dc:creator>George D Dangas</dc:creator>
<dc:creator>Raj Makkar</dc:creator>
<dc:creator>Nicolas M Van Mieghem</dc:creator>
<dc:date>2024-08-21</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Treatment of Transcatheter Aortic Valve Thrombosis: JACC Review Topic of the Week</dc:title>
<dc:identifier>pmid:39168571</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.064</dc:identifier>
</item>
<item>
<title>Structural Cardiac Interventions in Patients With Heart Failure: JACC Scientific Statement</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39168570/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240823180909&amp;v=2.18.0.post9+e462414
      <description>Pathologic left ventricular remodeling and valvular heart disease may contribute to the clinical presentation and outcomes of patients presenting with heart failure, and limit the effectiveness of guideline-directed medical therapy. Although surgical interventions including surgical ventricular restoration techniques and valve repair or replacement are effective therapies, there is growing evidence that transcatheter interventions may be options for patients with persistent symptoms of heart...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 27;84(9):832-847. doi: 10.1016/j.jacc.2024.05.061.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Pathologic left ventricular remodeling and valvular heart disease may contribute to the clinical presentation and outcomes of patients presenting with heart failure, and limit the effectiveness of guideline-directed medical therapy. Although surgical interventions including surgical ventricular restoration techniques and valve repair or replacement are effective therapies, there is growing evidence that transcatheter interventions may be options for patients with persistent symptoms of heart failure despite optimal medical therapy, where surgical options may be limited. This scientific statement will review the current available and investigational percutaneous strategies for the management of structural contributors to heart failure: dilated left ventricular cardiomyopathies and valvular heart disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39168570/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240823180909&v=2.18.0.post9+e462414">39168570</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.061>10.1016/j.jacc.2024.05.061</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39168570</guid>
<pubDate>Wed, 21 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Rebecca T Hahn</dc:creator>
<dc:creator>JoAnn Lindenfeld</dc:creator>
<dc:creator>Scott D Lim</dc:creator>
<dc:creator>Michael J Mack</dc:creator>
<dc:creator>Daniel Burkhoff</dc:creator>
<dc:date>2024-08-21</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Structural Cardiac Interventions in Patients With Heart Failure: JACC Scientific Statement</dc:title>
<dc:identifier>pmid:39168570</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.061</dc:identifier>
</item>
<item>
<title>Democratizing Congenital Heart Disease Management: The Potential for AI-Enabled Care and Necessary Future Directions</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39168569/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240823180909&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 27;84(9):829-831. doi: 10.1016/j.jacc.2024.06.019.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39168569/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240823180909&v=2.18.0.post9+e462414">39168569</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.019>10.1016/j.jacc.2024.06.019</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39168569</guid>
<pubDate>Wed, 21 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Sneha S Jain</dc:creator>
<dc:creator>Pierre Elias</dc:creator>
<dc:creator>Daniel E Clark</dc:creator>
<dc:date>2024-08-21</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Democratizing Congenital Heart Disease Management: The Potential for AI-Enabled Care and Necessary Future Directions</dc:title>
<dc:identifier>pmid:39168569</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.019</dc:identifier>
</item>
<item>
<title>Deep Learning-Based Electrocardiogram Analysis Predicts Biventricular Dysfunction and Dilation in Congenital Heart Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39168568/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240823180909&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: AI-ECG shows promise to predict biventricular dysfunction/dilation, which may help inform CMR timing in CHD.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 27;84(9):815-828. doi: 10.1016/j.jacc.2024.05.062.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Artificial intelligence-enhanced electrocardiogram (AI-ECG) analysis shows promise to detect biventricular pathophysiology. However, AI-ECG analysis remains underexplored in congenital heart disease (CHD).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The purpose of this study was to develop and externally validate an AI-ECG model to predict cardiovascular magnetic resonance (CMR)-defined biventricular dysfunction/dilation in patients with CHD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We trained (80%) and tested (20%) a convolutional neural network on paired ECG-CMRs (≤30 days apart) from patients with and without CHD to detect left ventricular (LV) dysfunction (ejection fraction ≤40%), RV dysfunction (ejection fraction ≤35%), and LV and RV dilation (end-diastolic volume z-score ≥4). Performance was assessed during internal testing and external validation on an outside health care system using area under receiver-operating curve (AUROC) and area under precision recall curve.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The internal and external cohorts comprised 8,584 ECG-CMR pairs (n = 4,941; median CMR age 20.7 years) and 909 ECG-CMR pairs (n = 746; median CMR age 25.4 years), respectively. Model performance was similar for internal testing (AUROC: LV dysfunction 0.87; LV dilation 0.86; RV dysfunction 0.88; RV dilation 0.81) and external validation (AUROC: LV dysfunction 0.89; LV dilation 0.83; RV dysfunction 0.82; RV dilation 0.80). Model performance was lowest in functionally single ventricle patients. Tetralogy of Fallot patients predicted to be at high risk of ventricular dysfunction had lower survival (P &lt; 0.001). Model explainability via saliency mapping revealed that lateral precordial leads influence all outcome predictions, with high-risk features including QRS widening and T-wave inversions for RV dysfunction/dilation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: AI-ECG shows promise to predict biventricular dysfunction/dilation, which may help inform CMR timing in CHD.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39168568/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240823180909&v=2.18.0.post9+e462414">39168568</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.062>10.1016/j.jacc.2024.05.062</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39168568</guid>
<pubDate>Wed, 21 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Joshua Mayourian</dc:creator>
<dc:creator>Addison Gearhart</dc:creator>
<dc:creator>William G La Cava</dc:creator>
<dc:creator>Akhil Vaid</dc:creator>
<dc:creator>Girish N Nadkarni</dc:creator>
<dc:creator>John K Triedman</dc:creator>
<dc:creator>Andrew J Powell</dc:creator>
<dc:creator>Rachel M Wald</dc:creator>
<dc:creator>Anne Marie Valente</dc:creator>
<dc:creator>Tal Geva</dc:creator>
<dc:creator>Son Q Duong</dc:creator>
<dc:creator>Sunil J Ghelani</dc:creator>
<dc:date>2024-08-21</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Deep Learning-Based Electrocardiogram Analysis Predicts Biventricular Dysfunction and Dilation in Congenital Heart Disease</dc:title>
<dc:identifier>pmid:39168568</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.062</dc:identifier>
</item>
<item>
<title>Frailty in Peripheral Artery Disease Patients Undergoing Revascularization: There Is Strength in Antithrombotic Therapy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39168567/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240823180909&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 27;84(9):812-814. doi: 10.1016/j.jacc.2024.05.059.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39168567/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240823180909&v=2.18.0.post9+e462414">39168567</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.059>10.1016/j.jacc.2024.05.059</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39168567</guid>
<pubDate>Wed, 21 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Umberto Campia</dc:creator>
<dc:creator>Giovanni Scimeca</dc:creator>
<dc:date>2024-08-21</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Frailty in Peripheral Artery Disease Patients Undergoing Revascularization: There Is Strength in Antithrombotic Therapy</dc:title>
<dc:identifier>pmid:39168567</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.059</dc:identifier>
</item>
<item>
<title>Low-Dose Rivaroxaban Plus Aspirin in Fragile Patients After Lower Extremity Revascularization</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39168566/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240823180909&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Patients with PAD after lower extremity revascularization meeting fragile criteria are at higher risk of ischemic complications and bleeding. Rivaroxaban reduces ischemic risk and increases bleeding regardless of frailty status. These data may assist in personalization of antithrombotic therapy in fragile population.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 27;84(9):801-811. doi: 10.1016/j.jacc.2024.05.060.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Rivaroxaban 2.5 mg plus aspirin reduced limb and cardiovascular events and increased bleeding in patients with symptomatic peripheral artery disease (PAD) after lower extremity revascularization in the VOYAGER PAD (Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities) study. Fragile patients are at heightened risk for ischemic and bleeding events.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The purpose of this study was to investigate the safety and efficacy of rivaroxaban 2.5 mg in fragile patients from VOYAGER PAD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Patients were categorized as fragile based on prespecified criteria (age >;75 years, weight ≤50 kg, or baseline estimated glomerular filtration rate &lt;50 mL/min/1.73 m<sup>2</sup>). The primary efficacy outcome was the composite of acute limb ischemia, major amputation of a vascular etiology, myocardial infarction, ischemic stroke, or cardiovascular death. The principal safety outcome was TIMI major bleeding.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 6,564 randomized patients, a total of 1,674 subjects were categorized as fragile at baseline. In the placebo arm, fragile patients were at higher risk of the primary outcome (HR: 1.34; 95% CI: 1.12-1.61) and TIMI major bleeding (HR: 1.57; 95% CI: 0.83-2.96), compared with nonfragile patients. The effect of rivaroxaban on the primary endpoint was not modified by frailty status (fragile HR: 0.93; 95% CI: 0.75-1.15; nonfragile HR: 0.83; 95% CI: 0.72-0.97; P interaction = 0.37). Rivaroxaban increased TIMI major bleeding in fragile (HR: 1.54; 95% CI: 0.82-2.91) and nonfragile patients (HR: 1.37; 95% CI: 0.84-2.23; P interaction = 0.65).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Patients with PAD after lower extremity revascularization meeting fragile criteria are at higher risk of ischemic complications and bleeding. Rivaroxaban reduces ischemic risk and increases bleeding regardless of frailty status. These data may assist in personalization of antithrombotic therapy in fragile population.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39168566/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240823180909&v=2.18.0.post9+e462414">39168566</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.060>10.1016/j.jacc.2024.05.060</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39168566</guid>
<pubDate>Wed, 21 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Mario Enrico Canonico</dc:creator>
<dc:creator>Cecilia C Low Wang</dc:creator>
<dc:creator>Judith Hsia</dc:creator>
<dc:creator>E Sebastian Debus</dc:creator>
<dc:creator>Mark R Nehler</dc:creator>
<dc:creator>Manesh R Patel</dc:creator>
<dc:creator>Sonia S Anand</dc:creator>
<dc:creator>Joseph Ycas</dc:creator>
<dc:creator>Warren H Capell</dc:creator>
<dc:creator>Eva Muehlhofer</dc:creator>
<dc:creator>Lloyd P Haskell</dc:creator>
<dc:creator>Scott D Berkowitz</dc:creator>
<dc:creator>Rupert Bauersachs</dc:creator>
<dc:creator>Marc P Bonaca</dc:creator>
<dc:date>2024-08-21</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Low-Dose Rivaroxaban Plus Aspirin in Fragile Patients After Lower Extremity Revascularization</dc:title>
<dc:identifier>pmid:39168566</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.060</dc:identifier>
</item>
<item>
<title>Olpasiran Pharmacodynamic Study: Ensuring We Go a Mile Deep But More Than an Inch Wide</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39168565/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240823180909&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 27;84(9):798-800. doi: 10.1016/j.jacc.2024.05.063.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39168565/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240823180909&v=2.18.0.post9+e462414">39168565</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.063>10.1016/j.jacc.2024.05.063</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39168565</guid>
<pubDate>Wed, 21 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Jared Alexander Spitz</dc:creator>
<dc:creator>Anandita Agarwala</dc:creator>
<dc:date>2024-08-21</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Olpasiran Pharmacodynamic Study: Ensuring We Go a Mile Deep But More Than an Inch Wide</dc:title>
<dc:identifier>pmid:39168565</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.063</dc:identifier>
</item>
<item>
<title>The Off-Treatment Effects of Olpasiran on Lipoprotein(a) Lowering: OCEAN(a)-DOSE Extension Period Results</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39168564/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240823180909&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Olpasiran is a potent siRNA with prolonged effects on Lp(a) lowering. Participants receiving doses ≥75 mg Q12W sustained a ∼40% to 50% reduction in Lp(a) levels close to 1 year after the last dose. (Olpasiran Trials of Cardiovascular Events And LipoproteiN[a] Reduction-DOSE Finding Study [OCEAN(a)-DOSE]; NCT04270760).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 27;84(9):790-797. doi: 10.1016/j.jacc.2024.05.058.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Olpasiran, a small interfering RNA (siRNA), blocks lipoprotein(a) (Lp(a)) production by preventing translation of apolipoprotein(a) mRNA. In phase 2, higher doses of olpasiran every 12 weeks (Q12W) reduced circulating Lp(a) by >;95%.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study sought to assess the timing of return of Lp(a) to baseline after discontinuation of olpasiran, as well as longer-term safety.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: OCEAN(a)-DOSE (Olpasiran Trials of Cardiovascular Events And LipoproteiN[a] Reduction-DOSE Finding Study) was a phase 2, dose-finding trial that enrolled 281 participants with atherosclerotic cardiovascular disease and Lp(a) >;150 nmol/L to 1 of 4 active doses of olpasiran vs placebo (10 mg, 75 mg, 225 mg Q12W, or an exploratory dose of 225 mg Q24W given subcutaneously). The last dose of olpasiran was administered at week 36; after week 48, there was an extended off-treatment follow-up period for a minimum of 24 weeks.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 276 (98.2%) participants entered the off-treatment follow-up period. The median study exposure (treatment combined with off-treatment phases) was 86 weeks (Q1-Q3: 79-99 weeks). For the 75 mg Q12W dose, the off-treatment placebo-adjusted mean percent change from baseline in Lp(a) was -76.2%, -53.0%, -44.0%, and -27.9% at 60, 72, 84, and 96 weeks, respectively (all P &lt; 0.001). The respective off-treatment changes in Lp(a) for the 225 mg Q12W dose were -84.4%, -61.6%, -52.2%, and -36.4% (all P &lt; 0.001). During the extension follow-up phase, no new safety concerns were identified.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Olpasiran is a potent siRNA with prolonged effects on Lp(a) lowering. Participants receiving doses ≥75 mg Q12W sustained a ∼40% to 50% reduction in Lp(a) levels close to 1 year after the last dose. (Olpasiran Trials of Cardiovascular Events And LipoproteiN[a] Reduction-DOSE Finding Study [OCEAN(a)-DOSE]; NCT04270760).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39168564/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240823180909&v=2.18.0.post9+e462414">39168564</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.058>10.1016/j.jacc.2024.05.058</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39168564</guid>
<pubDate>Wed, 21 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Michelle L O'Donoghue</dc:creator>
<dc:creator>Robert S Rosenson</dc:creator>
<dc:creator>J Antonio G López</dc:creator>
<dc:creator>Norman E Lepor</dc:creator>
<dc:creator>Seth J Baum</dc:creator>
<dc:creator>Elmer Stout</dc:creator>
<dc:creator>Daniel Gaudet</dc:creator>
<dc:creator>Beat Knusel</dc:creator>
<dc:creator>Julia F Kuder</dc:creator>
<dc:creator>Sabina A Murphy</dc:creator>
<dc:creator>Huei Wang</dc:creator>
<dc:creator>You Wu</dc:creator>
<dc:creator>Trupti Shah</dc:creator>
<dc:creator>Jingying Wang</dc:creator>
<dc:creator>Tomasz Wilmanski</dc:creator>
<dc:creator>Winnie Sohn</dc:creator>
<dc:creator>Helina Kassahun</dc:creator>
<dc:creator>Marc S Sabatine</dc:creator>
<dc:creator>OCEAN(a)-DOSE Trial Investigators</dc:creator>
<dc:date>2024-08-21</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The Off-Treatment Effects of Olpasiran on Lipoprotein(a) Lowering: OCEAN(a)-DOSE Extension Period Results</dc:title>
<dc:identifier>pmid:39168564</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.058</dc:identifier>
</item>
<item>
<title>A genetic basis for sex differences in Xp11 translocation renal cell carcinoma</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39168126/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240823180909&amp;v=2.18.0.post9+e462414
      <description>Xp11 translocation renal cell carcinoma (tRCC) is a rare, female-predominant cancer driven by a fusion between the transcription factor binding to IGHM enhancer 3 (TFE3) gene on chromosome Xp11.2 and a partner gene on either chromosome X (chrX) or an autosome. It remains unknown what types of rearrangements underlie TFE3 fusions, whether fusions can arise from both the active (chrXa) and inactive X (chrXi) chromosomes, and whether TFE3 fusions from chrXi translocations account for the female...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Aug 14:S0092-8674(24)00832-8. doi: 10.1016/j.cell.2024.07.038. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Xp11 translocation renal cell carcinoma (tRCC) is a rare, female-predominant cancer driven by a fusion between the transcription factor binding to IGHM enhancer 3 (TFE3) gene on chromosome Xp11.2 and a partner gene on either chromosome X (chrX) or an autosome. It remains unknown what types of rearrangements underlie TFE3 fusions, whether fusions can arise from both the active (chrXa) and inactive X (chrXi) chromosomes, and whether TFE3 fusions from chrXi translocations account for the female predominance of tRCC. To address these questions, we performed haplotype-specific analyses of chrX rearrangements in tRCC whole genomes. We show that TFE3 fusions universally arise as reciprocal translocations and that oncogenic TFE3 fusions can arise from chrXi:autosomal translocations. Female-specific chrXi:autosomal translocations result in a 2:1 female-to-male ratio of TFE3 fusions involving autosomal partner genes and account for the female predominance of tRCC. Our results highlight how X chromosome genetics constrains somatic chrX alterations and underlies cancer sex differences.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39168126/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240823180909&v=2.18.0.post9+e462414">39168126</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.07.038>10.1016/j.cell.2024.07.038</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39168126</guid>
<pubDate>Wed, 21 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Mingkee Achom</dc:creator>
<dc:creator>Ananthan Sadagopan</dc:creator>
<dc:creator>Chunyang Bao</dc:creator>
<dc:creator>Fiona McBride</dc:creator>
<dc:creator>Jiao Li</dc:creator>
<dc:creator>Prathyusha Konda</dc:creator>
<dc:creator>Richard W Tourdot</dc:creator>
<dc:creator>Qingru Xu</dc:creator>
<dc:creator>Maria Nakhoul</dc:creator>
<dc:creator>Daniel S Gallant</dc:creator>
<dc:creator>Usman Ali Ahmed</dc:creator>
<dc:creator>Jillian O'Toole</dc:creator>
<dc:creator>Dory Freeman</dc:creator>
<dc:creator>Gwo-Shu Mary Lee</dc:creator>
<dc:creator>Jonathan L Hecht</dc:creator>
<dc:creator>Eric C Kauffman</dc:creator>
<dc:creator>David J Einstein</dc:creator>
<dc:creator>Toni K Choueiri</dc:creator>
<dc:creator>Cheng-Zhong Zhang</dc:creator>
<dc:creator>Srinivas R Viswanathan</dc:creator>
<dc:date>2024-08-21</dc:date>
<dc:source>Cell</dc:source>
<dc:title>A genetic basis for sex differences in Xp11 translocation renal cell carcinoma</dc:title>
<dc:identifier>pmid:39168126</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.07.038</dc:identifier>
</item>
<item>
<title>Condensate interfacial forces reposition DNA loci and probe chromatin viscoelasticity</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39168125/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240823180909&amp;v=2.18.0.post9+e462414
      <description>Biomolecular condensates assemble in living cells through phase separation and related phase transitions. An underappreciated feature of these dynamic molecular assemblies is that they form interfaces with other cellular structures, including membranes, cytoskeleton, DNA and RNA, and other membraneless compartments. These interfaces are expected to give rise to capillary forces, but there are few ways of quantifying and harnessing these forces in living cells. Here, we introduce viscoelastic...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Aug 14:S0092-8674(24)00828-6. doi: 10.1016/j.cell.2024.07.034. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Biomolecular condensates assemble in living cells through phase separation and related phase transitions. An underappreciated feature of these dynamic molecular assemblies is that they form interfaces with other cellular structures, including membranes, cytoskeleton, DNA and RNA, and other membraneless compartments. These interfaces are expected to give rise to capillary forces, but there are few ways of quantifying and harnessing these forces in living cells. Here, we introduce viscoelastic chromatin tethering and organization (VECTOR), which uses light-inducible biomolecular condensates to generate capillary forces at targeted DNA loci. VECTOR can be utilized to programmably reposition genomic loci on a timescale of seconds to minutes, quantitatively revealing local heterogeneity in the viscoelastic material properties of chromatin. These synthetic condensates are built from components that naturally form liquid-like structures in living cells, highlighting the potential role for native condensates to generate forces and do work to reorganize the genome and impact chromatin architecture.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39168125/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240823180909&v=2.18.0.post9+e462414">39168125</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.07.034>10.1016/j.cell.2024.07.034</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39168125</guid>
<pubDate>Wed, 21 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Amy R Strom</dc:creator>
<dc:creator>Yoonji Kim</dc:creator>
<dc:creator>Hongbo Zhao</dc:creator>
<dc:creator>Yi-Che Chang</dc:creator>
<dc:creator>Natalia D Orlovsky</dc:creator>
<dc:creator>Andrej Košmrlj</dc:creator>
<dc:creator>Cornelis Storm</dc:creator>
<dc:creator>Clifford P Brangwynne</dc:creator>
<dc:date>2024-08-21</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Condensate interfacial forces reposition DNA loci and probe chromatin viscoelasticity</dc:title>
<dc:identifier>pmid:39168125</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.07.034</dc:identifier>
</item>
<item>
<title>Dynamic regulation of tissue fluidity controls skin repair during wound healing</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39168124/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240823180909&amp;v=2.18.0.post9+e462414
      <description>During wound healing, different pools of stem cells (SCs) contribute to skin repair. However, how SCs become activated and drive the tissue remodeling essential for skin repair is still poorly understood. Here, by developing a mouse model allowing lineage tracing and basal cell lineage ablation, we monitor SC fate and tissue dynamics during regeneration using confocal and intravital imaging. Analysis of basal cell rearrangements shows dynamic transitions from a solid-like homeostatic state to a...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Aug 11:S0092-8674(24)00825-0. doi: 10.1016/j.cell.2024.07.031. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">During wound healing, different pools of stem cells (SCs) contribute to skin repair. However, how SCs become activated and drive the tissue remodeling essential for skin repair is still poorly understood. Here, by developing a mouse model allowing lineage tracing and basal cell lineage ablation, we monitor SC fate and tissue dynamics during regeneration using confocal and intravital imaging. Analysis of basal cell rearrangements shows dynamic transitions from a solid-like homeostatic state to a fluid-like state allowing tissue remodeling during repair, as predicted by a minimal mathematical modeling of the spatiotemporal dynamics and fate behavior of basal cells. The basal cell layer progressively returns to a solid-like state with re-epithelialization. Bulk, single-cell RNA, and epigenetic profiling of SCs, together with functional experiments, uncover a common regenerative state regulated by the EGFR/AP1 axis activated during tissue fluidization that is essential for skin SC activation and tissue repair.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39168124/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240823180909&v=2.18.0.post9+e462414">39168124</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.07.031>10.1016/j.cell.2024.07.031</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39168124</guid>
<pubDate>Wed, 21 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Rahul M Sarate</dc:creator>
<dc:creator>Joel Hochstetter</dc:creator>
<dc:creator>Manon Valet</dc:creator>
<dc:creator>Adrien Hallou</dc:creator>
<dc:creator>Yura Song</dc:creator>
<dc:creator>Nordin Bansaccal</dc:creator>
<dc:creator>Melanie Ligare</dc:creator>
<dc:creator>Mariaceleste Aragona</dc:creator>
<dc:creator>Dan Engelman</dc:creator>
<dc:creator>Anaïs Bauduin</dc:creator>
<dc:creator>Otger Campàs</dc:creator>
<dc:creator>Benjamin D Simons</dc:creator>
<dc:creator>Cedric Blanpain</dc:creator>
<dc:date>2024-08-21</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Dynamic regulation of tissue fluidity controls skin repair during wound healing</dc:title>
<dc:identifier>pmid:39168124</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.07.031</dc:identifier>
</item>
<item>
<title>Female representation on editorial boards of the National Societies of Cardiology Journals of the European Society of Cardiology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39167698/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240823180909&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 21:ehae418. doi: 10.1093/eurheartj/ehae418. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39167698/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240823180909&v=2.18.0.post9+e462414">39167698</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae418>10.1093/eurheartj/ehae418</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39167698</guid>
<pubDate>Wed, 21 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Dilek Ural</dc:creator>
<dc:creator>Jean Jacques Monsuez</dc:creator>
<dc:creator>Anetta Undas</dc:creator>
<dc:date>2024-08-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Female representation on editorial boards of the National Societies of Cardiology Journals of the European Society of Cardiology</dc:title>
<dc:identifier>pmid:39167698</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae418</dc:identifier>
</item>





























</channel>
</rss>